Originally posted by pivalde
This is now correct, in 1 year development has been poor and we are today on the same level as 2 y ago. During the previous year share price came from this 1.60 level up almost 100 %. But even 3.18 is very poor value if you compare what it was just before the results of Imagine study. So I do agree totally that market has lost much of its interest in this stock if you look at the share price. On the volume side evidence is not so clear ( volumes are low ) and volatility is very high.
The value of this stock is only in it's goal: to help neurodegeneration patient with the drugs it has developed. If it cannot help them there is no hope with Prana but if it can and does it better than other drug companies there is still a great future IMO. But this is only my opinion and it is not an advice to anybody to invest in Prana.
Hi pivalde, my take here is that this is just another fluctuation. They slowly walk the price down with no news, then drive it back up with or without news. Progress is painfully slow in this neurodegeneration drug space. Note nobody has developed an effective AD drug, and that includes pharma's with multi billion dollar R&D budgets. PSP drug development sent one small company I was following broke. Nobody has developed an effective ALS treatment. Animal models have not been very successful. The last successful HD drug development, led by Dr Stamler's team for Auspex (now Prana's Dr Stamler) was an adaptation of the previous approved HD drug. Prana's Ira Shoulson was instrumental in the approval of both drugs tetrabenazine and dutetetrabenazine. These guys are now in Prana's US based development team for PBT434. I fail to see how there could be no hope here. Auspex was acquired by the giant Teva for $3.2 billion in enterprise value and approximately $3.5 billion in equity value in 2015.
I think Prana could be more forthcoming on info from the screening of new compounds using the new 3D human neuron model they now have. I guess there will be news as patents are registered?
Note, as far as I can see Auspex had no approved drugs at the time of the acquisition and was founded in 2001. Dutetetrabenazine had completed phase3.
All just my opinion. DYOR
